Join to view full profile
30 Winter StreetBoston, MA 02108
Phone+1 774-303-0668
Dr. Kasturi is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Rush University Medical CenterResidency, Internal Medicine, 1992 - 1995
Rush Medical College of Rush University Medical CenterClass of 1992
Certifications & Licensure
MA State Medical License 1999 - 2027
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise E HR Modular, Allscripts, 2012-2014, 2016
- CMS Meaningful Use Stage 1 Certification Meaningful Use Advisor, MedCPU Inc., 2012-2014, 2016
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2014, 2016
Clinical Trials
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
- Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Publications & Presentations
PubMed
- 1 citationsEstimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients.Jeffrey Thomas Yorio, Aviva G Asnis-Alibozek, Vijay Kasturi, Thomas E Hutson
BMC Health Services Research. 2024-10-25 - 8 citationsLong-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.Kathryn E Beckermann, Aviva G Asnis-Alibozek, Michael B Atkins, Bernard Escudier, Thomas E Hutson
The Oncologist. 2024-03-04 - 3 citationsActivity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.Pedro C Barata, Alexander Chehrazi-Raffle, Kimberly D Allman, Aviva Asnis-Alibozek, Vijay Kasturi
The Oncologist. 2023-10-03
Press Mentions
Landmark Study in Non-Muscle Invasive Bladder Cancer Evaluating Breakthrough Investigational Gene Therapy Nadofaragene Firadenovec Published in the Lancet OncologyNovember 30th, 2020- Chutes & Ladders—Novavax Appoints AstraZeneca Vet Dubovsky to CMO RoleJune 19th, 2020
- Boehringer Ingelheim Nabs New US President and CEO; AstraZeneca Vet Hops Aboard Novavax as CMOJune 19th, 2020
Committees
- Chair, Protocol Review Committee, UMass Cancer Center 2011 - 2015
Professional Memberships
- Member
- Member
- IASLCMember
- SITCMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: